[go: up one dir, main page]

NO952261L - Antacidium Compounds and Methods of Preparation thereof - Google Patents

Antacidium Compounds and Methods of Preparation thereof

Info

Publication number
NO952261L
NO952261L NO952261A NO952261A NO952261L NO 952261 L NO952261 L NO 952261L NO 952261 A NO952261 A NO 952261A NO 952261 A NO952261 A NO 952261A NO 952261 L NO952261 L NO 952261L
Authority
NO
Norway
Prior art keywords
antacidium
compounds
preparation
methods
composition
Prior art date
Application number
NO952261A
Other languages
Norwegian (no)
Other versions
NO952261D0 (en
Inventor
Gary G Liversidge
Gregory L Mcintire
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Publication of NO952261L publication Critical patent/NO952261L/en
Publication of NO952261D0 publication Critical patent/NO952261D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Antacld sammensetning som omfatter partikler bestående vesentlig av et alumlnlum-basert nøytrallserlngsmiddel som har en gjennomsnittlig partlkkelstørrelse som er mindre enn omtrent 3 mikroner og en fremgangsmåte for fremstilling av sammensetningen er beskrevet. Disse sammensetningene utviser betydelig forsterkede nøytrallseringsrater 1 forhold til sammensetninger som Inneholder større partikler og er nyttige for be-handling av pattedyr med smerter assosiert med sur mave.An analgesic composition comprising particles consisting essentially of an aluminum-based neutralizing agent having an average particle size of less than about 3 microns and a process for preparing the composition is described. These compositions exhibit significantly enhanced neutralization rates relative to compositions containing larger particles and are useful for treating mammals with abdominal pain.

NO952261A 1992-12-11 1995-06-08 Antacidium Compounds and Methods of Preparation thereof NO952261D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98929692A 1992-12-11 1992-12-11
PCT/US1993/011720 WO1994013304A2 (en) 1992-12-11 1993-12-03 Antacid composition and method of production

Publications (2)

Publication Number Publication Date
NO952261L true NO952261L (en) 1995-06-08
NO952261D0 NO952261D0 (en) 1995-06-08

Family

ID=25534976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952261A NO952261D0 (en) 1992-12-11 1995-06-08 Antacidium Compounds and Methods of Preparation thereof

Country Status (10)

Country Link
EP (1) EP0673253A1 (en)
JP (1) JPH08504442A (en)
KR (1) KR950703982A (en)
AU (1) AU6390894A (en)
CA (1) CA2150383A1 (en)
CZ (1) CZ148695A3 (en)
FI (1) FI952859A (en)
NO (1) NO952261D0 (en)
SK (1) SK76595A3 (en)
WO (1) WO1994013304A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3618348B2 (en) * 1993-08-24 2005-02-09 カッパ ファーマシューティカルズ リミテッド Reduced absorption of fatty acids
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US5874112A (en) * 1997-03-31 1999-02-23 Mcneil Ppc-Inc. Translucent antacid suspension
AU2002951438A0 (en) * 2002-09-17 2002-10-03 Nauveau Technology Investments Ltd Methods and compositions for treatment of excess stomach acid in mammals
RU2013148719A (en) * 2013-10-31 2015-05-10 Геннадий Гильфанович Галимов COMPOSITION BASED ON MAGNESIUM CHLORIDE HYDROXOALUMINATE, CONTAINING MAGNESIUM HYDROXIDE, AS A THERAPEUTIC DRUG
WO2016104367A1 (en) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ Functional dyspepsia therapeutic drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
FR2512344A1 (en) * 1981-09-08 1983-03-11 Af Aplicaciones Far Lab Stable antacid suspension of aluminium and/or magnesium hydroxide(s) - prepd. by mixing powdered prod. with water, fragmenting and dispersing to give particle size of 5-10 microns

Also Published As

Publication number Publication date
JPH08504442A (en) 1996-05-14
FI952859A0 (en) 1995-06-09
WO1994013304A2 (en) 1994-06-23
KR950703982A (en) 1995-11-17
CA2150383A1 (en) 1994-06-23
EP0673253A1 (en) 1995-09-27
NO952261D0 (en) 1995-06-08
AU6390894A (en) 1994-07-04
CZ148695A3 (en) 1995-12-13
SK76595A3 (en) 1997-01-08
FI952859A (en) 1995-06-09
WO1994013304A3 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
FR2450608A1 (en) CARCINOSTATIC AND IMMUNOSTIMULATING AGENT CONTAINING A LYSOPHOSPHOLIPID AND A PHOSPHOLIPIDE AND METHOD FOR PREPARING THE SAME
MX9603831A (en) Antithrombotic agents.
CA2094267A1 (en) Use of fatty alcohol based composition for preparing emulsions, method of preparing emulsions and emulsions so obtained
IL106640A (en) Pharmaceutical compositions for the treatment and prevention of irritable bowel syndrome
PL321848A1 (en) Cell adhesion inhibitors
NZ513960A (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
GB9418912D0 (en) Pharmaceutically active compounds
NO952261L (en) Antacidium Compounds and Methods of Preparation thereof
ES8306371A1 (en) Stable S-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle.
IT1240473B (en) PROCEDURE TO IMPROVE THE THERAPEUTIC EFFICACY OF LIPOSOLUBLE CORTICOSTEROIDS AND COMPOSITION FOR THE IMPLEMENTATION OF SUCH PROCEDURE
IL105090A0 (en) Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
CA2046308A1 (en) Radiolabeled colloid compositions, their use and process for their preparation
DE69433012D1 (en) METHOD FOR PRODUCING ORAL DOSAGE FORMULATIONS CONTAINING DICLOFENAC
AU7155887A (en) Thiodiazolylurea-containing agent for defoliating plants
GEP20032968B (en) Use of Ketolides in Pharmaceutical Compositions for Preventing Thrombotic Arterial Complications Linked to Atherosclerosis
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
EP0135189A3 (en) Pharmaceutically useful malonamides
KR960700701A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING PARACETAMOL AND L-CYSTEINE OR A PRECURSOR THEREOF
PT74931A (en) Process for preparing n-(aryloxyalkyl)-n'-(aminoalkyl) ureas and of pharmaceutical compositions containing the same
FR2604903B1 (en) THERAPEUTIC AGENTS IN THE FORM OF SUBMICROSCOPIC PARTICLES AGAINST PARASITOSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ509881A (en) Micronised pharmaceutical compositions containing colistin sulphomethate sodium
EP0154886A3 (en) Carboxyalkyl dipeptide derivatives, process for their preparation, agents containing them, and their use